<?xml version="1.0" encoding="UTF-8"?><document xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" type="pharmaledger-1.0" xsi:noNamespaceSchemaLocation="pharmaleger-leaflet-v3.xsd">

  


<section id="d1e531e96-9b25-4d58-b63f-9b8c8b33bcb0" level="1"><header id="ForTheUseOnlyOfRegisteredPulmonolog-FD0CFD27" style="text-align: center;"><i>For the use
only of Registered Pulmonologists</i></header></section>
<section id="d303a991c-8f16-4776-877d-d489ea765080" level="1"><header id="d9bcbccb6-cad8-40ac-b4b6-4db4e01a7b97" style="text-align: center;"><b>NUCALA 100 mg</b></header></section>
<section id="d0c9b263a-aaac-49aa-a273-975491bba2b7" level="1"><header id="GENERICNAME-FD0D33FF" style="text-align: left;"><b>1. Name</b> </header>
<p id="p900312301717492317" style="text-align: left;" class="Generic_Name"><b>Mepolizumab Powder for Solution for Injection using class</b></p></section>
<section id="dad2fd409-e7d2-4888-8d42-dab45ac54adb" level="1"><header id="QUALITATIVEANDQUANTITATIVECOMPOSITI-FD0D40DF" style="text-align: left;"><b>2.   QUALITATIVE AND QUANTITATIVE
COMPOSITION</b></header><p id="db3789849-fd4a-408f-83a1-33de4c90ea65" style="text-align: left;">Each vial contains 100
mg mepolizumab. After reconstitution, each ml of solution contains
100 mg mepolizumab.</p><p id="dc17f47ff-1617-44bd-89f6-eab0c3f659ae" style="text-align: left;">Mepolizumab is a humanised
monoclonal antibody produced in Chinese hamster ovary cells by recombinant
DNA technology.</p><p id="d9f0b502f-4454-4b09-ae02-ee6521b08942" style="text-align: left;"><b><u>List of
excipients</u></b></p><p class="List_Excipients" id="SucroseSodiumPhosphateDibasicHeptah-FD25AFBB" style="text-align: left;">Sucrose<br/>Sodium phosphate dibasic heptahydrate<br/>Polysorbate 80<br/>Hydrochloric acid<br/>Water for Injection</p></section>
<section id="db5e16efc-d4fb-4c8e-9e0e-a116d108f552" level="1"><header id="DOSAGEFORMANDSTRENGTH-FD0D8D4F" style="text-align: left;"><b>3.   DOSAGE FORM AND STRENGTH</b></header><p id="d56170fbe-06b9-4844-b1ca-e12e53165c70" style="text-align: left;">Powder for solution for
injection in vial.</p><p id="p847714301717492508" style="text-align: left;">Lyophilised white powder.</p></section>
<section id="d9b894655-290b-4aa7-a81d-5934bd8c9713" level="1"><header id="CLINICALPARTICULARS-FD0DA182" style="text-align: left;"><b>4.   CLINICAL PARTICULARS</b></header><p id="dd48823bc-aa21-421c-960b-d6f1b725f9f8" style="text-align: left;"><b>4.1.  Therapeutic
indications</b></p><p id="d78552436-127e-4f76-bec6-beab8f91cbd2" style="text-align: left;"><i>NUCALA</i> is indicated as an add-on treatment for severe refractory eosinophilic
asthma in adult patients (see section <i>5.1. Pharmacodynamic
properties</i>).</p><p id="d16140a2c-a30f-469e-b483-d9c028c4222b" style="text-align: left;"><b>4.2.  Posology and
Method of Administration</b></p><p id="dacfcbb66-cc02-47fb-a9b8-b36d819865be" style="text-align: left;"><i>NUCALA</i> should be prescribed by physicians experienced in the diagnosis
and treatment of severe refractory eosinophilic asthma.</p><p id="d1b264370-bffa-4632-9809-bb53e6b98652" style="text-align: left;"><b><i>Posology</i></b></p><p id="d995068c5-6d58-48b5-a1e1-a6f85350a797" style="text-align: left;"><i>Adults</i></p><p id="d4366ac48-f2fe-479a-ac57-50c13fcf22f4" style="text-align: left;">The recommended dose of mepolizumab is 100 mg administered subcutaneously
once every 4 weeks. </p><p id="d1122177d-7152-435e-8e53-6626faf646e0" style="text-align: left;"><i>NUCALA</i> is intended for long-term treatment. The need for continued therapy
should be considered at least on an annual basis as determined by
physician assessment of the patient’s disease severity and level of
control of exacerbations.</p><p id="d51a02cd4-b551-4fb3-b8db-0ef6a8c585a6" style="text-align: left;"><u>Special populations</u></p><p id="db88b178e-775a-445f-817a-5c12456248de" style="text-align: left;"><i>Paediatric population</i></p><p id="dd0a97639-4214-4437-bd3f-675145df6c2a" style="text-align: left;">The safety and efficacy
of  <i>NUCALA</i>  in children and adolescents under 18
years of age has not yet been established. Very limited data are currently
available in children 12 to 18  years old (see sections <i>4.8.
Undesirable effects</i>, <i>5.1. Pharmacodynamic properties</i> and <i>5.2. Pharmacokinetic properties</i>)  therefore
no recommendations can be made.</p><p id="d5ea52234-7591-4057-ba4d-8cbe953549b0" style="text-align: left;"><i>Elderly patients</i></p><p id="d7d4339b1-7c21-48b2-af16-aeb80126112e" style="text-align: left;">No dose adjustment is required for elderly patients (see section <i>5.2. Pharmacokinetic properties</i>).</p><p id="df2c7e24c-368d-46a4-bb65-525fcb77db87" style="text-align: left;"><i>Renal and hepatic
impairment</i></p><p id="da8321f8e-b890-4c83-9c9c-775465055e2c" style="text-align: left;">No dose adjustment is required
 in  patients with renal or hepatic impairment (see section <i>5.2. Pharmacokinetic properties</i>).</p><p id="d50807bb5-0b2d-43af-9ff1-c02a6af1c2c9" style="text-align: left;"><b><i>Method of
administration</i></b></p><p id="d3c1cac80-81b4-43a2-bc05-f4179171f1e7" style="text-align: left;"><i>NUCALA</i> is for subcutaneous injection only and should be administered by
a healthcare professional. It may be injected into the upper arm,
thigh, or abdomen.</p><p id="d66699f08-cd03-48d0-8a12-37579fb64b75" style="text-align: left;">The powder should be reconstituted
prior to administration and the reconstituted solution should be used
immediately. For instructions on the reconstitution of the medicinal
product before administration, see section <i>8.5. Special precautions
for disposal.</i></p><p id="d2e5ffcbf-c710-46b8-8fc0-7dcd6ed8dd50" style="text-align: left;"><b>4.3.  Contraindications</b></p><p id="d3355a72a-54b5-4ea1-8f50-baf39fd715e9" style="text-align: left;">Hypersensitivity to the active substance or to any of the excipients
listed in section <i>2. Qualitative and Quantitative composition. </i></p><p id="d03846af0-1899-4e4d-b477-34d9cd0274db" style="text-align: left;"><b>4.4.  Special Warnings and Precautions for Use </b></p><p id="deccd9ac8-2f7a-47f2-9234-e2da06d18663" style="text-align: left;"><b><i>Asthma exacerbations</i></b></p><p id="d7fc104cc-4b90-45eb-a0a8-7587ac0a890a" style="text-align: left;">Mepolizumab should not
be used to treat acute asthma exacerbations.</p><p id="Asthma-relatedAdverseEventsOrExacer-FD0E762C" style="text-align: left;">Asthma-related adverse
events or exacerbations may occur during treatment. Patients should
be instructed to seek medical advice if their asthma remains uncontrolled
or worsens after initiation of treatment.</p><p id="d23304fca-0eb2-467b-bbab-22f33d29fb89" style="text-align: left;"><b><i>Corticosteroids</i></b></p><p id="d203635cf-2ad2-4a23-b342-343c43095fc3" style="text-align: left;">Abrupt discontinuation
of corticosteroids after initiation of mepolizumab therapy is not
recommended. Reduction in corticosteroid doses, if required, should
be gradual and performed under the supervision of a physician.</p><p id="daf88e62b-da69-4a16-8263-f56be79ca1c3" style="text-align: left;"><b><i>Hypersensitivity and administration-related reactions</i></b></p><p id="da92b727a-fa9f-4ac5-a39f-7dbd4abfcb0c" style="text-align: left;">Acute and delayed systemic reactions, including hypersensitivity
reactions (e.g. anaphylaxis, urticaria, angioedema, rash, bronchospasm,
hypotension), have occurred following administration of mepolizumab.
These reactions generally occur within hours of administration, but
in some instances have a delayed onset (i.e., typically within several
days). These reactions may occur for the first time after a long duration
of treatment (see section <i>4.8. Undesirable effects</i>).</p><p id="d81340f66-cac9-49d7-b83a-39ca88c0f59a" style="text-align: left;"><b><i>Parasitic infections</i></b></p><p id="dc1bca70b-2cf2-4dc8-b096-72b7e3ea27e5" style="text-align: left;">Eosinophils may be involved
in the immunological response to some helminth infections. Patients
with pre-existing helminth infections should be treated before starting
therapy. If patients become infected whilst receiving treatment with
mepolizumab and do not respond to anti-helminth treatment, temporary
discontinuation of therapy should be considered.</p><p id="dd3bed385-d8c7-45e5-af28-1adea8661c73" style="text-align: left;"><b><i>Excipients</i></b></p><p id="d2dcbc40e-2486-4af3-8033-3a24192bd02d" style="text-align: left;">This medicinal product
contains less than 1 mmol sodium (23 mg) per 100 mg dose, that is
to say essentially “sodium-free”.</p><p id="dffc201bf-dabe-4733-8af4-eb52d39c5c6e" style="text-align: left;"><b>4.5.  Drugs Interactions</b></p><p id="d9154d635-c74a-4084-8288-e4387e17f3e8" style="text-align: left;">No interaction studies have been performed.</p><p id="daeb84dec-10fb-4982-9561-a07e1195dc2d" style="text-align: left;">Cytochrome P450 enzymes,
efflux pumps and protein-binding mechanisms are not involved in the
clearance of mepolizumab. Increased levels of pro-inflammatory cytokines
(e.g. IL-6), via interaction with their cognate receptors on hepatocytes,
have been shown to suppress the formation of CYP450 enzymes and drug
transporters, however, elevation of systemic pro-inflammatory markers
in severe asthma is minimal and there is no evidence of IL-5 receptor
alpha expression on hepatocytes. The potential for drug-drug interactions
with mepolizumab is therefore considered low.</p><p id="d65fa0d62-1501-4ee7-a647-fbe2d5a281d5" style="text-align: left;"><b>4.6.  Use in Special
Populations</b></p><p id="d5582ff51-7d1a-47c4-bfad-df4afc5be2ed" style="text-align: left;"><b><i>Pregnancy</i></b></p><p id="d3f92ba64-1882-4187-8a1a-479b79a69049" style="text-align: left;">There is a limited amount
of data (less than 300 pregnancy outcomes) from the use of mepolizumab
in pregnant women.</p><p id="d92568ed2-c6d8-4de8-ada1-6bbcba853289" style="text-align: left;">Mepolizumab crosses the
placental barrier in monkeys.  Animal studies do not indicate reproductive
toxicity (see section<i> 6.Nonclinical properties</i>. The
potential for harm to a human fetus is unknown.</p><p id="d22af99b8-853b-40a2-88a2-b7569daba4cf" style="text-align: left;">As a precautionary measure,
it is preferable to avoid the use of <i>NUCALA</i> during
pregnancy. Administration of<b> </b><i>NUCALA</i><b> </b>to pregnant women should only be considered if the expected
benefit to the mother is greater than any possible risk to the fetus.</p><p id="dc7a02fb1-6199-4ae3-b704-e286a7f06c41" style="text-align: left;"><b><i>Lactation</i></b></p><p id="d46489c00-9bd5-4d3e-b465-af1e01e1d767" style="text-align: left;">There are no data regarding
the excretion of mepolizumab in human milk.  However, mepolizumab
was excreted into the milk of cynomolgous monkeys at concentrations
of less than 0.5% of those detected in plasma.</p><p id="d7ee0cb4d-eed9-4ae6-9ddf-0325667a1502" style="text-align: left;">A decision must be made
whether to discontinue breast-feeding or to discontinue <i>NUCALA</i> therapy taking into account the benefit of breast-feeding for the
child and the benefit of therapy for the woman.</p><p id="d5a7e5579-2c36-44d2-b044-1589e040b6bb" style="text-align: left;"><b><i>Fertility</i></b></p><p id="d6d2c71aa-13c0-4455-8d59-a1f3420bb62b" style="text-align: left;">There are no fertility
data in humans. Animal studies showed no adverse effects of anti-IL5
treatment on fertility (see section <i> 6. Nonclinical properties</i>).</p><p id="d977e05c0-8f20-4e7d-a0f4-367f18691362" style="text-align: left;"><b>4.7.  Effects on Ability to Drive and Use Machines</b></p><p id="dcd91ec77-efee-4004-937d-400e1378da1b" style="text-align: left;"><i>NUCALA</i> has no or negligible influence on the ability to drive and use machines.</p><p id="d64b5bf76-b0d5-4de7-990e-3fa7578c3c76" style="text-align: left;"><b>4.8.
 Undesirable Effects</b></p><p id="db077e2f0-9705-44d7-b975-1d398ecf8093" style="text-align: left;"><b><i>Summary of
the safety profile</i></b></p><p id="d4908c600-6396-4a1d-ad9b-fbf3b87ab345" style="text-align: left;">In clinical studies in
subjects with severe refractory eosinophilic asthma, the most commonly
reported adverse reactions during treatment were headache, injection
site reactions and back pain.</p><p id="dfafbd585-58bf-43b8-8375-9f9fb37316ef" style="text-align: left;"><b><i>Tabulated
list of adverse reactions</i></b></p><p id="d6bc88758-fb34-4b9f-b722-26902adaa278" style="text-align: left;">A total of 915 subjects
with severe refractory eosinophilic asthma have received either a
subcutaneous or an intravenous dose of mepolizumab during clinical
studies of 24 to 52 weeks duration. The table below presents the adverse
reactions from the two placebo controlled studies in patients receiving
mepolizumab 100 mg subcutaneously (n=263).</p><p id="dcda425bd-2a3d-402e-9128-f66e34928874" style="text-align: left;">The frequency of adverse
reactions is defined using the following convention: very common (≥1/10);
common (≥1/100 to &lt;1/10); uncommon (≥1/1,000 to &lt;1/100); rare
(≥1/10,000 to &lt;1/1,000); very rare (&lt;1/10,000); and not known
(cannot be estimated from available data). Within each frequency grouping,
adverse reactions are presented in order of decreasing seriousness.</p><p style="font-size: 0pt; margin-top: 15pt; margin-bottom: 0pt;"> </p><table cellspacing="0" id="SystemOrganClassAdverseReactionsFre-FD0FAE42" ID="SystemOrganClassAdverseReactionsFre-FD0FAE42" border="1" width="100%" style="border-collapse:collapse; border-spacing: 0pt; margin:0pt; ">
<tr>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p97381301717493908" style="text-align: left;"><b>System Organ Class</b></p></td>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p97421301717493926" style="text-align: left;"><b>Adverse Reactions</b></p></td>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p97481301717493947" style="text-align: left;"><b>Frequency</b></p></td>
</tr>
<tr>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p97521301717494092" style="text-align: left;">Infections &amp; infestations</p></td>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p97551301717494117" style="text-align: left;">Lower respiratory tract infection<br/>Urinary tract infection<br/>Pharyngitis</p></td>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p97591301717494166" style="text-align: left;">Common</p></td>
</tr>
<tr>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p97611301717494181" style="text-align: left;">Immune system disorders</p></td>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p97631301717494192" style="text-align: left;">Hypersensitivity reactions
(systemic allergic)*<br/>Anaphylaxis**</p></td>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p97651301717494201" style="text-align: left;">Common<br/>Rare</p></td>
</tr>
<tr>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p97671301717494244" style="text-align: left;">Nervous system disorders</p></td>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p97691301717494251" style="text-align: left;">Headache</p></td>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p97711301717494260" style="text-align: left;">Very common</p></td>
</tr>
<tr>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p130831301717503996" style="text-align: left;">Respiratory, thoracic and
mediastinal disorders</p></td>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p130851301717504001" style="text-align: left;">Nasal congestion</p></td>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p130871301717504005" style="text-align: left;">Common</p></td>
</tr>
<tr>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p131051301717504089" style="text-align: left;">Gastrointestinal disorders</p></td>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p130971301717504071" style="text-align: left;">Abdominal pain upper</p></td>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p130891301717504009" style="text-align: left;">Common</p></td>
</tr>
<tr>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p133131301717504093" style="text-align: left;">Skin and subcutaneous tissue
disorders</p></td>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p130991301717504076" style="text-align: left;">Eczema</p></td>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p130911301717504013" style="text-align: left;">Common</p></td>
</tr>
<tr>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p133151301717504098" style="text-align: left;">Musculoskeletal and connective
tissue disorders</p></td>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p131011301717504079" style="text-align: left;">Back pain</p></td>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p130931301717504017" style="text-align: left;">Common</p></td>
</tr>
<tr>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p133171301717504103" style="text-align: left;">General disorders and administration
site conditions</p></td>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p131031301717504084" style="text-align: left;">Administration-related reactions
(systemic non allergic)***<br/>Local injection site reactions<br/>Pyrexia</p></td>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p130951301717504021" style="text-align: left;">Common</p></td>
</tr>
</table><p style="font-size: 0pt; margin-top: 0pt; margin-bottom: 14pt;"> </p><p id="ddc4874c7-5ceb-4fab-ba17-f7516ef67341" style="text-align: left;">* Systemic
reactions including hypersensitivity have been reported at an overall
incidence comparable to that of placebo. For examples of the associated
manifestations reported and a description of the time to onset, see
section <i>4.4. Special Warnings and Precautions for Use.</i></p><p id="db3e61e8b-e7c7-4e9a-a950-45f9cdf90d88" style="text-align: left;"> **From spontaneous post marketing reporting.</p><p id="TheMostCommonManifestationsAssociat-FD107973" style="text-align: left;">*** The most common
manifestations associated with reports of systemic non-allergic administration-related
reactions were rash, flushing and myalgia; these manifestations were
reported infrequently and in &lt;1% of subjects receiving mepolizumab
100 mg subcutaneously.</p><p id="dd97b5358-8412-4581-819d-963c8f7de5f0" style="text-align: left;"><b><i>Description
of selected adverse reaction</i></b></p><p id="d062960e4-4130-47f6-bfc5-f707454b9bf3" style="text-align: left;"><u>Local injection
site reactions</u></p><p id="d20cb5b77-d601-4627-a881-fa6a8a617ff8" style="text-align: left;">In placebo-controlled studies
the incidence of local injection site reactions with mepolizumab 100 mg
subcutaneous and placebo was 8% and 3%, respectively. These events
were all non-serious, mild to moderate in intensity and the majority
resolved within a few days. Local injection site reactions occurred
mainly at the start of treatment and within the first 3 injections
with fewer reports on subsequent injections. The most common manifestations
reported with these events included pain, erythema, swelling, itching,
and burning sensation.</p><p id="dca8352bf-6d4a-4fd2-be51-53a2cc58b6a7" style="text-align: left;"><u>Paediatric population</u></p><p id="d65f6a7df-16ad-454d-bf87-926e7ea6f464" style="text-align: left;">The clinical trial data currently available in paediatric patients
is too limited to characterise the safety profile of mepolizumab in
this population (see section <i>5.1. Pharmacodynamic properties</i>). However, the frequency, type and severity of adverse reactions
in the paediatric population are expected to be similar to those seen
in adults.</p><p id="ddf8ba366-939a-4caa-9ca3-7372cc731818" style="text-align: left;"><b>4.9.  Overdose</b></p><p id="df852c422-863a-4d90-ae3f-addcb1cdcb35" style="text-align: left;">Single doses of up to 1500 mg were administered intravenously in
a clinical trial to patients with eosinophilic disease without evidence
of dose-related toxicities.</p><p id="df63d802b-9949-4fcf-8743-b933b5310b17" style="text-align: left;">There is no specific treatment
for an overdose with mepolizumab. If overdose occurs, the patient
should be treated supportively with appropriate monitoring as necessary.</p><p id="p99951301717494691" style="text-align: left;">Further management should be as
clinically indicated or as recommended by the national poisons centre,
where available.</p></section>
<section id="d0bb60b1e-1673-4167-a121-e72622b71ce0" level="1"><header id="PHARMACOLOGICALPROPERTIES-FD10F943" style="text-align: left;"><b>5.   PHARMACOLOGICAL PROPERTIES</b></header><p id="d4d92583f-ae8a-412d-b2c2-5e992d785cc6" style="text-align: left;">Pharmacotherapeutic group:
Drugs for obstructive airway diseases, other systemic drugs for obstructive
airway diseases, ATC code: R03DX09<i>.</i><i> </i></p><p id="d43f4a602-3db3-4d4a-a668-4d5e3435c124" style="text-align: left;"><b>5.1.  Mechanism of Action</b></p><p id="dcdde46ee-620e-4a3b-ae93-45c4c889a4ec" style="text-align: left;">Mepolizumab is a humanised
monoclonal antibody (IgG1, kappa), which targets human interleukin‑5
(IL‑5) with high affinity and specificity. IL‑5 is the major cytokine
responsible for the growth and differentiation, recruitment, activation
and survival of eosinophils. Mepolizumab inhibits the bioactivity
of IL-5 with nanomolar potency by blocking the binding of IL‑5 to
the alpha chain of the IL-5 receptor complex expressed on the eosinophil
cell surface, thereby inhibiting IL-5 signalling and reducing the
production and survival of eosinophils.</p><p id="d1a62d2bb-4a4c-4a8a-94fc-0e133ff24a9d" style="text-align: left;"><b>5.2.  Pharmacodynamic
Properties</b></p><p id="d749db0f6-9872-47e4-86a5-87eea089343c" style="text-align: left;">Following a dose of 100 mg
administered subcutaneously every 4 weeks for 32 weeks, blood eosinophils
were reduced from a geometric<b> </b>mean count at baseline
of 290 to 40 cells/µL at week 32 (N=182), a reduction of 84% compared
to placebo. This magnitude of reduction was observed within 4 weeks
of treatment.</p><p id="d776d689c-75fc-4de7-8d85-8cbef87b3d98" style="text-align: left;"><b><i>Immunogenicity</i></b></p><p id="d7a646ace-6b07-4c9e-8a3e-93af19ed106a" style="text-align: left;">Consistent with the potentially
immunogenic properties of protein and peptide therapeutics, patients
may develop antibodies to mepolizumab following treatment. In the
placebo-controlled trials, 15/260 (6%) of subjects treated with 100 mg
dose subcutaneously developed anti-mepolizumab antibodies after having
received at least one dose of mepolizumab. Neutralising antibodies
were detected in one subject. Anti-mepolizumab antibodies did not
discernibly impact the pharmacokinetics and pharmacodynamics of mepolizumab
in the majority of patients and there was no evidence of a correlation
between antibody titres and change in blood eosinophil level.</p><p id="de891e587-331b-40d8-922a-84678e8b246b" style="text-align: left;"><b><i>Clinical efficacy</i></b></p><p id="d39f3d7ac-21d5-46f3-a35e-9ee1c19560af" style="text-align: left;">The efficacy of mepolizumab
in the treatment of a targeted group of patients with severe refractory
eosinophilic asthma was evaluated in 3 randomised, double-blind, parallel-group
clinical studies of between 24-52 weeks duration, in patients aged
12 years and older. These patients either remained uncontrolled (at
least two severe exacerbations in the previous 12 months) on their
current standard of care, including at least high doses of inhaled
corticosteroids (ICS) plus an additional maintenance treatment(s),
or were dependent on systemic corticosteroids. Additional maintenance
treatments included long-acting beta<sub>2 </sub>-adrenergic
agonists (LABA), leukotriene modifiers, long-acting muscarinic antagonists
(LAMA), theophylline, and oral corticosteroids (OCS).</p><p id="d85a94e3b-1b6b-4331-9614-1ba9e4b861c7" style="text-align: left;">The two exacerbations studies
MEA112997 and MEA115588 enrolled a total of 1192 patients, 60% females,
with a mean age of 49 years (range 12– 82). The proportion of patients
on maintenance OCS was 31% and 24%, respectively. Patients were required
to have a history of two or more severe asthma exacerbations requiring
oral or systemic corticosteroid treatment in the past 12 months and
reduced lung function at baseline (pre-bronchodilator FEV<sub>1</sub>&lt;80% in adults and &lt;90% in adolescents).The mean
number of exacerbations in the previous year was 3.6 and the mean
predicted pre-bronchodilator FEV<sub>1</sub> was 60%.
Patients continued to receive their existing asthma medicine during
the studies<b><i>.</i></b></p><p id="d8ffc8da7-e40a-453a-98c5-686bab642339" style="text-align: left;">For the oral corticosteroid-sparing
study MEA115575, a total of 135 patients were enrolled (55% were female;
mean age of 50 years) who were being treated daily with OCS (5-35 mg
per day), and high-dose ICS plus an additional maintenance medicine.</p><p id="d92eb5eb5-a338-4360-97a9-ec3579c39bc2" style="text-align: left;"><b><i>Dose-ranging efficacy MEA112997 (DREAM) study</i></b></p><p id="d0cb5e711-b52f-4cee-a1cc-908e47af9fe5" style="text-align: left;">In MEA112997,
a randomised, double-blind, placebo-controlled, parallel-group, multi-centre
study of 52 weeks duration in 616 patients with severe refractory
eosinophilic asthma, mepolizumab significantly reduced clinically
significant asthma exacerbations (defined as worsening of asthma requiring
use of oral/systemic corticosteroids and/or hospitalisation and/or
emergency department visits) when administered in doses of 75 mg,
250 mg or 750 mg intravenously compared to placebo (see Table 1).</p><p id="d481e1760-1867-486d-aeaf-1a9d0bc6c76c" style="text-align: left;"><b>Table
1: Frequency of clinically significant exacerbations at week 52 in
the intent to treat population</b></p><p style="font-size: 0pt; margin-top: 15pt; margin-bottom: 0pt;"> </p><table cellspacing="0" id="d374ef7b0-8d15-474c-aeb8-e5a758adf935" ID="d374ef7b0-8d15-474c-aeb8-e5a758adf935" border="1" width="100%" style="border-collapse:collapse; border-spacing: 0pt; margin:0pt; ">
<tr>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;" rowspan="2"> </td>
<td align="center" style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;" colspan="3"><p id="p100073301717503711" style="text-align: left;">Intravenous Mepolizumab</p></td>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p100105301717503722" style="text-align: left;">Placebo</p></td>
</tr>
<tr>
<td align="center" style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p100125301717503732" style="text-align: left;">75mg<br/>n=153</p></td>
<td align="center" style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p128471301717503803" style="text-align: left;">250mg<br/>n=152</p></td>
<td align="center" style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p128491301717503812" style="text-align: left;">750mg<br/>n=156</p></td>
<td align="center" style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p130571301717503817" style="text-align: left;">n= 155</p></td>
</tr>
<tr>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p128311301717503751" style="text-align: left;">Exacerbation rate/year</p></td>
<td align="center" style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p128391301717503773" style="text-align: left;">1.24</p></td>
<td align="center" style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p100145301717503737" style="text-align: left;">1.46</p></td>
<td align="center" style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p128263301717503742" style="text-align: left;">1.15</p></td>
<td align="center" style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p128291301717503747" style="text-align: left;">2.40</p></td>
</tr>
<tr>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p128331301717503757" style="text-align: left;">Percent reduction</p></td>
<td align="center" style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p128411301717503780" style="text-align: left;">48%</p></td>
<td align="center" style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p128431301717503785" style="text-align: left;">39%</p></td>
<td align="center" style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p128451301717503792" style="text-align: left;">52%</p></td>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"> </td>
</tr>
<tr>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p128351301717503761" style="text-align: left;">Rate ratio (95% CI)</p></td>
<td align="center" style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p130591301717503822" style="text-align: left;">0.52 (0.39,
0.69)</p></td>
<td align="center" style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p130631301717503832" style="text-align: left;">0.61(0.46,
0.81)</p></td>
<td align="center" style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p130671301717503841" style="text-align: left;">0.48 (0.36,
0.64)</p></td>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"> </td>
</tr>
<tr>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p128371301717503768" style="text-align: left;">p-value</p></td>
<td align="center" style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p130611301717503827" style="text-align: left;">&lt;0.001</p></td>
<td align="center" style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p130651301717503837" style="text-align: left;">&lt;0.001</p></td>
<td align="center" style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p130691301717503847" style="text-align: left;">&lt;0.001</p></td>
<td align="center" style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p130711301717503852" style="text-align: left;">-</p></td>
</tr>
</table><p id="d2eac73c2-546c-44a6-a16d-9fccc0339ab8" style="text-align: left;"><b><i>Exacerbation reduction (MEA115588) MENSA study</i></b></p><p id="d92d32c9f-4f4a-49ac-aa65-cc9fbb0f67b7" style="text-align: left;">MEA115588 was a randomised, double-blind, placebo-controlled, parallel-group,
multi-centre study which evaluated the efficacy and safety of mepolizumab
as add-on therapy in 576 patients with severe refractory eosinophilic
asthma defined as peripheral blood eosinophils greater than or equal
to 150 cells/μL at initiation of treatment or greater than or equal
to 300 cells/μL within the past 12 months.</p><p id="PatientsReceivedMepolizumab100MgAdm-FD121AB3" style="text-align: left;">Patients received
mepolizumab 100 mg administered subcutaneously, mepolizumab 75 mg
administered intravenously or placebo treatment once every 4 weeks
over 32 weeks. The primary endpoint was the frequency of clinically
significant exacerbations of asthma and the reductions for both mepolizumab
treatment arms compared to placebo were statistically significant
(p&lt;0.001). Table 2 provides the results of the primary and secondary
endpoints for patients treated with subcutaneous mepolizumab or placebo.</p><p id="df269f2b0-c604-4846-b081-b6fa3bf0706a" style="text-align: left;"><b>Table
2: Results of primary and secondary endpoints at week 32 in the intent
to treat population (MEA115588)</b></p><p style="font-size: 0pt; margin-top: 15pt; margin-bottom: 0pt;"> </p><table cellspacing="0" id="d015409ba-42f9-48c6-8c0b-d4192474365c" ID="d015409ba-42f9-48c6-8c0b-d4192474365c" border="1" width="100%" style="border-collapse:collapse; border-spacing: 0pt; margin:0pt; ">
<tr>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"> </td>
<td align="center" style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p120731301717502439" style="text-align: left;">Mepolizumab
100 mg<br/>(subcutaneous)<br/>N= 194</p></td>
<td align="center" style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p120791301717502465" style="text-align: left;">Placebo<br/>N= 191</p></td>
</tr>
<tr>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;" colspan="3"><p id="p122892301717502508" style="text-align: left;"><b>Primary
endpoint</b></p></td>
</tr>
<tr>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;" colspan="3"><p id="p122932301717502528" style="text-align: left;"><b>Frequency
of clinically significant exacerbations</b></p></td>
</tr>
<tr>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p122972301717502591" style="text-align: left;">Exacerbation rate per year</p></td>
<td align="center" style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p122992301717502597" style="text-align: left;">0.83</p></td>
<td align="center" style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p123012301717502603" style="text-align: left;">1.74</p></td>
</tr>
<tr>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p123032301717502676" style="text-align: left;">Percent reduction<br/>Rate ratio (95% CI)</p></td>
<td align="center" style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p123052301717502683" style="text-align: left;">53%<br/>0.47 (0.35, 0.64)</p></td>
<td align="center" style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p123072301717502691" style="text-align: left;">-</p></td>
</tr>
<tr>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p123092301717502710" style="text-align: left;">p-value</p></td>
<td align="center" style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p123132301717502749" style="text-align: left;">&lt;0.001</p></td>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"> </td>
</tr>
<tr>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;" colspan="3"><p id="p123152301717502758" style="text-align: left;"><b>Secondary
endpoints</b></p></td>
</tr>
<tr>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;" colspan="3"><p id="p123192301717502771" style="text-align: left;"><b>Frequency
of exacerbations requiring hospitalisations/emergency room visits</b></p></td>
</tr>
<tr>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p123232301717502828" style="text-align: left;">Exacerbation rate per year</p></td>
<td align="center" style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p123252301717502833" style="text-align: left;">0.08</p></td>
<td align="center" style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p87450301717502845" style="text-align: left;">0.20</p></td>
</tr>
<tr>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p123292301717502854" style="text-align: left;">Percent reduction<br/>Rate ratio (95% CI)</p></td>
<td align="center" style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p123332301717502871" style="text-align: left;">61%<br/>0.39 (0.18, 0.83)</p></td>
<td align="center" style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p123352301717502879" style="text-align: left;">_</p></td>
</tr>
<tr>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p125451301717503018" style="text-align: left;">p-value</p></td>
<td align="center" style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p125471301717503022" style="text-align: left;">0.015</p></td>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"> </td>
</tr>
<tr>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;" colspan="3"><p id="p125491301717503033" style="text-align: left;"><b>Frequency
of exacerbations requiring hospitalisation</b></p></td>
</tr>
<tr>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p125531301717503053" style="text-align: left;">Exacerbations rate per year</p></td>
<td align="center" style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p125551301717503058" style="text-align: left;">0.03</p></td>
<td align="center" style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p125571301717503064" style="text-align: left;">0.10</p></td>
</tr>
<tr>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p125591301717503094" style="text-align: left;">Percent reduction<br/>Rate ratio (95% CI)</p></td>
<td align="center" style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p125631301717503105" style="text-align: left;">69%<br/>0.31 (0.11, 0.91)</p></td>
<td align="center" style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;">_</td>
</tr>
<tr>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p125671301717503176" style="text-align: left;">p-value</p></td>
<td align="center" style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p125691301717503183" style="text-align: left;">0.034</p></td>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"> </td>
</tr>
<tr>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;" colspan="3"><p id="p125711301717503196" style="text-align: left;"><b>Pre-bronchodilator
FEV<sub>1</sub> (mL) at week 32</b></p></td>
</tr>
<tr>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p125791301717503224" style="text-align: left;">Baseline (SD)</p></td>
<td align="center" style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p125811301717503233" style="text-align: left;">1730 (659)</p></td>
<td align="center" style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p125831301717503237" style="text-align: left;">1860 (631)</p></td>
</tr>
<tr>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p125851301717503255" style="text-align: left;">Mean Change from Baseline
(SE)</p></td>
<td align="center" style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p125871301717503263" style="text-align: left;">183 (31)</p></td>
<td align="center" style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p125891301717503269" style="text-align: left;">86 (31)</p></td>
</tr>
<tr>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p125911301717503293" style="text-align: left;">Difference (mepolizumab vs.
placebo)</p></td>
<td align="center" style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p125931301717503308" style="text-align: left;">98</p></td>
<td align="center" style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"> </td>
</tr>
<tr>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p128011301717503317" style="text-align: left;">95% CI</p></td>
<td align="center" style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p128031301717503323" style="text-align: left;">(11, 184)</p></td>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"> </td>
</tr>
<tr>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p128051301717503332" style="text-align: left;">p-value</p></td>
<td align="center" style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p128071301717503343" style="text-align: left;">0.028</p></td>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"> </td>
</tr>
<tr>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;" colspan="3"><p id="p128091301717503374" style="text-align: left;"><b>St. George’s
Respiratory Questionnaire (SGRQ) at week 32</b></p></td>
</tr>
<tr>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p38873301717503413" style="text-align: left;">Baseline (SD)</p></td>
<td align="center" style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p38843301717503419" style="text-align: left;">47.9 (19. 5)</p></td>
<td align="center" style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p38813301717503426" style="text-align: left;">46.9 (19.8)</p></td>
</tr>
<tr>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p38793301717503491" style="text-align: left;">Mean Change from Baseline (SE)</p></td>
<td align="center" style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p38833301717503496" style="text-align: left;">-16.0 (1.1)</p></td>
<td align="center" style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p128131301717503503" style="text-align: left;">-9.0 (1.2)</p></td>
</tr>
<tr>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p128151301717503512" style="text-align: left;">Difference (mepolizumab vs.
placebo)</p></td>
<td align="center" style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p128171301717503521" style="text-align: left;">-7.0</p></td>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"> </td>
</tr>
<tr>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p128191301717503527" style="text-align: left;">95% CI</p></td>
<td align="center" style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p128211301717503533" style="text-align: left;">(-10.2, -3.8)</p></td>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"> </td>
</tr>
<tr>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p128231301717503539" style="text-align: left;">p-value</p></td>
<td align="center" style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p128251301717503545" style="text-align: left;">&lt;0.001</p></td>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"> </td>
</tr>
</table><p id="d0ddff3f9-e8b4-4a35-9e52-a78faecefc4e" style="text-align: left;"><b><i>Reduction of exacerbation rate by baseline blood eosinophil
count</i></b></p><p id="d4bea244b-f567-40cb-836c-91d45e24fce7" style="text-align: left;">Table 3 shows the results
of a combined analysis of the two exacerbation studies (MEA112997
and MEA115588) by baseline blood eosinophil count. The rate of exacerbations
in the placebo arm increased with increasing baseline blood eosinophil
count. The reduction rate with mepolizumab was greater in patients
with higher blood eosinophil counts.</p><p id="d8a0f7207-6f85-423d-b92b-4522f4958896" style="text-align: left;"><b>Table 3: Combined
analysis of the rate of clinically significant exacerbations by baseline
blood eosinophil count in patients with severe refractory eosinophilic
asthma</b></p><p style="font-size: 0pt; margin-top: 15pt; margin-bottom: 0pt;"> </p><table cellspacing="0" id="d90eeca3b-3306-4d12-88e0-33f79645cdf5" ID="d90eeca3b-3306-4d12-88e0-33f79645cdf5" border="1" width="100%" style="border-collapse:collapse; border-spacing: 0pt; margin:0pt; ">
<tr>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"> </td>
<td align="center" style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p115691301717501292" style="text-align: left;">Mepolizumab
75 mg IV/100 mg SC<br/>N=538</p></td>
<td align="center" style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p117791301717501307" style="text-align: left;">Placebo<br/>N=346</p></td>
</tr>
<tr>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;" colspan="3"><p id="p117831301717501322" style="text-align: left;"><b>MEA112997+MEA115588</b></p></td>
</tr>
<tr>
<td style="margin:0in; border-right:none; border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p117871301717501335" style="text-align: left;"><b>&lt;150 cells/μL</b></p></td>
<td style="margin:0in; border-right:none; border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"> </td>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"> </td>
</tr>
<tr>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p100173301717501357" style="text-align: left;">n </p></td>
<td align="center" style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p100165301717501366" style="text-align: left;">123</p></td>
<td align="center" style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p117903301717501372" style="text-align: left;">66</p></td>
</tr>
<tr>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p117931301717501379" style="text-align: left;">Exacerbation rate per year</p></td>
<td align="center" style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p117951301717501384" style="text-align: left;">1.16</p></td>
<td align="center" style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p117971301717501392" style="text-align: left;">1.73</p></td>
</tr>
<tr>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p117991301717501399" style="text-align: left;">Mepolizumab vs. placebo</p></td>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"> </td>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"> </td>
</tr>
<tr>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p118011301717501406" style="text-align: left;">Rate ratio (95% CI)</p></td>
<td align="center" style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p118031301717501414" style="text-align: left;">0.67 (0.46,0.98)</p></td>
<td align="center" style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p118051301717501422" style="text-align: left;">---</p></td>
</tr>
<tr>
<td style="margin:0in; border-right:none; border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p118071301717501430" style="text-align: left;"><b>150 to &lt;300 cells/μL</b></p></td>
<td style="margin:0in; border-right:none; border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"> </td>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"> </td>
</tr>
<tr>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p118111301717501441" style="text-align: left;">n </p></td>
<td align="center" style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p118131301717501449" style="text-align: left;">139</p></td>
<td align="center" style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p118151301717501454" style="text-align: left;">86</p></td>
</tr>
<tr>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p118171301717501459" style="text-align: left;">Exacerbation rate per year</p></td>
<td align="center" style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p118191301717501468" style="text-align: left;">1.01</p></td>
<td align="center" style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p118211301717501473" style="text-align: left;">1.41</p></td>
</tr>
<tr>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p118231301717501519" style="text-align: left;">Mepolizumab vs. placebo</p></td>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"> </td>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"> </td>
</tr>
<tr>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p118251301717501533" style="text-align: left;">Rate ratio (95% CI)</p></td>
<td align="center" style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p120331301717501539" style="text-align: left;">0.72 (0.47,1.10)</p></td>
<td align="center" style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p120351301717501544" style="text-align: left;">---</p></td>
</tr>
<tr>
<td style="margin:0in; border-right:none; border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p120371301717501561" style="text-align: left;"><b>300 to &lt;500 cells/μL</b></p></td>
<td style="margin:0in; border-right:none; border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"> </td>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"> </td>
</tr>
<tr>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p120431301717501577" style="text-align: left;">n </p></td>
<td align="center" style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p120403301717501595" style="text-align: left;">109</p></td>
<td align="center" style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p120451301717501600" style="text-align: left;">76</p></td>
</tr>
<tr>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p120471301717501612" style="text-align: left;">Exacerbation rate per year</p></td>
<td align="center" style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p120491301717501621" style="text-align: left;">1.02</p></td>
<td align="center" style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p120511301717501775" style="text-align: left;">1.64</p></td>
</tr>
<tr>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p120531301717501783" style="text-align: left;">Mepolizumab vs. placebo</p></td>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"> </td>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"> </td>
</tr>
<tr>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p120551301717501790" style="text-align: left;">Rate ratio (95% CI)</p></td>
<td align="center" style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p120571301717501795" style="text-align: left;">0.62 (0.41,0.93)</p></td>
<td align="center" style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p120591301717501841" style="text-align: left;">---</p></td>
</tr>
<tr>
<td style="margin:0in; border-right:none; border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p120611301717501853" style="text-align: left;"><b>≥500 cells/μL</b></p></td>
<td style="margin:0in; border-right:none; border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"> </td>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"> </td>
</tr>
<tr>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p100233301717501895" style="text-align: left;">n </p></td>
<td align="center" style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p51623301717501900" style="text-align: left;">162</p></td>
<td align="center" style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p51593301717501907" style="text-align: left;">116</p></td>
</tr>
<tr>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p51563301717501922" style="text-align: left;">Exacerbation rate per year</p></td>
<td align="center" style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p51543301717501930" style="text-align: left;">0.67</p></td>
<td align="center" style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p51615301717501936" style="text-align: left;">2.49</p></td>
</tr>
<tr>
<td style="margin:0in; border-right:none; border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;">Mepolizumab vs. placebo</td>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"> </td>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"> </td>
</tr>
<tr>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p120671301717501970" style="text-align: left;">Rate ratio (95% CI)</p></td>
<td align="center" style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p120691301717501976" style="text-align: left;">0.27 (0.19,0.37)</p></td>
<td align="center" style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p120711301717501982" style="text-align: left;">---</p></td>
</tr>
</table><p id="d3d2903c9-322d-4d7e-a468-fd12b283aa71" style="text-align: left;"><b><i>Oral corticosteroid reduction study MEA115575 (SIRIUS)</i></b></p><p id="dc1aeab47-59fc-406b-89f1-6e3427908595" style="text-align: left;">MEA115575 evaluated the
effect of mepolizumab 100 mg administered subcutaneously on reducing
the requirement for maintenance oral corticosteroids (OCS) while maintaining
asthma control in subjects with severe refractory eosinophilic asthma.
Patients had a blood eosinophil count of ≥150/μL at baseline or a
blood eosinophil count of ≥300/μL in the 12 months prior to screening.
Patients were administered mepolizumab or placebo treatment once every
4 weeks over the treatment period. Patients continued to receive their
existing asthma medicine during the study with the exception of their
OCS dose which was reduced every 4 weeks during the OCS reduction
phase (Weeks 4-20), as long as asthma control was maintained.</p><p id="d6d074600-f2d0-484f-a3ec-95da14d97b19" style="text-align: left;">A total of
135 patients were enrolled: mean age was 50 years, 55% were female,
and 48% had been receiving oral steroid therapy for at least 5 years.
The baseline mean prednisone equivalent dose was approximately 13 mg
per day.</p><p id="d94e1092b-30f1-4f8d-bb21-00c647f37e9b" style="text-align: left;">The primary endpoint was
the percent reduction in daily OCS dose (weeks 20-24), whilst maintaining
asthma control by defined dose reduction categories (see Table 4).
Predefined categories included percent reductions ranging from 90-100%
reduction, to no decrease in the prednisone dose from the end of the
optimisation phase. The comparison between mepolizumab and placebo
was statistically significant (p=0.008).</p><p id="dd8a6d807-3810-4c1e-a75e-641b56ac2c87" style="text-align: left;"><b>Table 4: Results
of the primary and secondary endpoints in MEA115575</b></p><p style="font-size: 0pt; margin-top: 15pt; margin-bottom: 0pt;"> </p><table cellspacing="0" id="da7b393ca-29d6-4337-8433-411165dfd03f" ID="da7b393ca-29d6-4337-8433-411165dfd03f" border="1" width="100%" style="border-collapse:collapse; border-spacing: 0pt; margin:0pt; ">
<tr>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"> </td>
<td align="center" style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;" colspan="2"><p id="p112783301717500530" style="text-align: left;">ITT Population</p></td>
</tr>
<tr>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"> </td>
<td align="center" style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p112831301717500548" style="text-align: left;">Mepolizumab<br/>100 mg<br/>(subcutaneous)<br/>N= 69</p></td>
<td align="center" style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p112911301717500575" style="text-align: left;">Placebo<br/>N= 66</p></td>
</tr>
<tr>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;" colspan="3"><p id="p112951301717500606" style="text-align: left;"><b>Primary
endpoint</b></p></td>
</tr>
<tr>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;" colspan="3"><p id="p113011301717500629" style="text-align: left;"><b>Percent
reduction in OCS from baseline (weeks 20-24)</b></p></td>
</tr>
<tr>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;" rowspan="4"><p id="p113031301717500647" style="text-align: left;">90% - 100%<br/>75% - &lt;90%<br/>50% - &lt;75%<br/>&gt;0% - &lt;50%<br/>No decrease in OCS/lack of asthma control/ withdrawal from treatment</p></td>
<td align="center" style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;" rowspan="4"><p id="p58935301717500790" style="text-align: left;">16 (23%)<br/>12 (17%)<br/>9 (13%)<br/>7 (10%)<br/>25 (36%)</p></td>
<td align="center" style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;" rowspan="4"><p id="p59133301717500854" style="text-align: left;">7(11%)<br/>5 (8%)<br/>10 (15%)<br/>7(11%)<br/>37 (56%)</p></td>
</tr>
<tr/>
<tr/>
<tr/>
<tr>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p113111301717500894" style="text-align: left;">Odds ratio (95% CI)</p></td>
<td align="center" style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p113131301717500905" style="text-align: left;">2.39 (1.25,
4.56)</p></td>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"> </td>
</tr>
<tr>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p115231301717500919" style="text-align: left;">p-value</p></td>
<td align="center" style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p115211301717500912" style="text-align: left;">0.008</p></td>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"> </td>
</tr>
<tr>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;" colspan="3"><p id="p115251301717500947" style="text-align: left;"><b>Secondary
endpoints (weeks 20-24)</b></p></td>
</tr>
<tr>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p115291301717501042" style="text-align: left;">Reduction in the daily OCS
dose to 0 mg/d</p></td>
<td align="center" style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p115311301717501050" style="text-align: left;">10 (14%)</p></td>
<td align="center" style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p115331301717501056" style="text-align: left;">5 (8%)</p></td>
</tr>
<tr>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p115351301717501068" style="text-align: left;">Odds ratio (95% CI)</p></td>
<td align="center" style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p115371301717501075" style="text-align: left;">1.67 (0.49,
5.75)</p></td>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"> </td>
</tr>
<tr>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p100293301717501097" style="text-align: left;">p-value</p></td>
<td align="center" style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p115383301717501106" style="text-align: left;">0. 414</p></td>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"> </td>
</tr>
<tr>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p115411301717501120" style="text-align: left;">Reduction in the daily OCS
dose to ≤5mg/day</p></td>
<td align="center" style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p115431301717501127" style="text-align: left;">37 (54%)</p></td>
<td align="center" style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p115451301717501133" style="text-align: left;">21 (32%)</p></td>
</tr>
<tr>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p115471301717501146" style="text-align: left;">Odds ratio (95% CI)</p></td>
<td align="center" style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p115491301717501152" style="text-align: left;">2.45 (1.12,
5.37)</p></td>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"> </td>
</tr>
<tr>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p115511301717501160" style="text-align: left;">p-value</p></td>
<td align="center" style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p115531301717501166" style="text-align: left;">0.025</p></td>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"> </td>
</tr>
<tr>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p115551301717501174" style="text-align: left;">Median % reduction in daily
OCS dose from baseline (95% CI)</p></td>
<td align="center" style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p115571301717501179" style="text-align: left;">50.0 (20.0,
75.0)</p></td>
<td align="center" style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p115591301717501185" style="text-align: left;">0.0 (-20.0,
33.3)</p></td>
</tr>
<tr>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p115611301717501195" style="text-align: left;">Median difference (95% CI)</p></td>
<td align="center" style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p115631301717501202" style="text-align: left;">-30.0 (-66.7,
0.0)</p></td>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"> </td>
</tr>
<tr>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p115651301717501210" style="text-align: left;">p-value</p></td>
<td align="center" style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"><p id="p115671301717501219" style="text-align: left;">0.007</p></td>
<td style="margin:0in; border-right:solid black .75pt;border-bottom:solid black .75pt;border-left:solid black .75pt;border-top:solid black .75pt;"> </td>
</tr>
</table><p style="font-size: 0pt; margin-top: 0pt; margin-bottom: 14pt;"> </p><p id="deb8c9777-9a83-4d1c-b9db-a55a1fdf072c" style="text-align: left;"><b><i>Paediatric population</i></b></p><p id="dd92ae8e3-ec2b-4c47-a64c-d9da230f7b2f" style="text-align: left;">There were 25 adolescents
13 girls and 12 boys, 9 aged 12 -14 years and 16 aged 15-17 years
enrolled in study MEA115588. Of the total 25 subjects: 9 received
placebo, 9 received mepolizumab 75 mg intravenously, and 7 received
100 mg subcutaneously. The same proportion of subjects (3/9) receiving
placebo and mepolizumab intravenously reported clinically significant
exacerbations; no exacerbations were reported in those receiving mepolizumab
subcutaneously. </p><p id="d680c882d-b31b-4255-9831-7544b719737a" style="text-align: left;"><b>5.3.  Pharmacokinetic
Properties</b></p><p id="d0eae30e1-f14c-43bf-a8ca-d013a13df893" style="text-align: left;">Following subcutaneous
dosing in patients with asthma, mepolizumab exhibited approximately
dose-proportional pharmacokinetics over a dose range of 12.5 mg to
250 mg.</p><p id="d9a6680b7-82c6-4562-9465-ff7c6d726f21" style="text-align: left;"><b><i>Absorption</i></b></p><p id="dc41154f2-f14e-40ac-bb3c-0cef3eeef3d4" style="text-align: left;">Following subcutaneous
administration to healthy subjects or patients with asthma, mepolizumab
was absorbed slowly with a median time to reach maximum plasma concentration
(T<sub>max</sub>) ranging from 4 to 8 days.</p><p id="d080a1035-0f51-424d-8aba-9e6cc993ea83" style="text-align: left;">Following a
single subcutaneous administration in the abdomen, thigh or arm of
healthy subjects, mepolizumab absolute bioavailability was 64%, 71%
and 75%, respectively. In patients with asthma the absolute bioavailability
of mepolizumab administered subcutaneously in the arm ranged from
74-80%.  Following repeat subcutaneous administration every 4 weeks,
there is approximately a two-fold accumulation at steady state.</p><p id="da50dbad1-159e-402f-b52a-de8e9171b861" style="text-align: left;"><b><i>Distribution</i></b></p><p id="d9ef13ab0-e3ba-4fa4-b207-212143f4747b" style="text-align: left;">Following a single intravenous
administration to patients with asthma, mepolizumab distributes into
a mean volume of distribution of 55 to 85 mL/kg.</p><p id="d18e7bd43-e819-46fb-9170-1660854b2eb8" style="text-align: left;"><b><i>Biotransformation</i></b></p><p id="d84796016-171d-42e9-9615-5f3e393ca692" style="text-align: left;">Mepolizumab is a humanized
IgG1 monoclonal antibody degraded by proteolytic enzymes which are
widely distributed in the body and not restricted to hepatic tissue.</p><p id="dba362144-0de6-4942-adec-8e7441371310" style="text-align: left;"><b><i>Elimination</i></b></p><p id="df03bbfcc-ec61-49e5-944e-ca1814d41da0" style="text-align: left;">Following a single intravenous
administration to patients with asthma, the mean systemic clearance
(CL) ranged from 1.9 to 3.3 mL/day/kg, with a mean terminal half-life
of approximately 20 days.  Following subcutaneous administration of
mepolizumab the mean terminal half-life (t1/2) ranged from 16 to 22
days. In the population pharmacokinetic analysis estimated mepolizumab
systemic clearance was 3.1 mL/day/kg.</p><p id="d2a927293-704e-4e4d-8ddd-abffad263f51" style="text-align: left;"><b><i>Paediatric
population</i></b></p><p id="ThereAreLimitedPharmacokineticDataA-FDAF8BF4" style="text-align: left;">There are limited
pharmacokinetic data available in the paediatric population<b><i> </i></b>(59 subjects with eosinophilic esophagitis, 19 subjects
with severe asthma)<b><i>. </i></b>Intravenous mepolizumab
pharmacokinetics was evaluated by population pharmacokinetic analysis
in a paediatric study conducted in subjects aged 2–17 years old with
eosinophilic esophagitis. Paediatric pharmacokinetics was largely
predictable from adults, after taking into account bodyweight. Mepolizumab
pharmacokinetics in adolescent subjects with severe eosinophilic asthma
included in the phase 3 studies were consistent with adults (see section <i>4.2. Posology and method of administration</i>).</p><p id="d139a031a-1f44-490e-90e3-02955ef5f9de" style="text-align: left;"><b>Special
populations</b></p><p id="d96b29f79-0a17-4298-80f2-dd871810a31a" style="text-align: left;"><i>Elderly patients
(</i>≥<i>65 years old)</i></p><p id="da6265e47-dc0b-4552-a90c-41aa7b01e69f" style="text-align: left;">There are limited pharmacokinetic
data available in elderly patients (≥65 years old) across all clinical
studies (N=90). However, in the population pharmacokinetic analysis,
there were no indications of an effect of age on the pharmacokinetics
of mepolizumab over the age range of 12 to 82 years.</p><p id="dc65d9f98-df74-4688-ad5c-c962718e326f" style="text-align: left;"><i>Renal impairment</i></p><p id="db3377bad-2242-45df-a498-2f6aa8fd6e35" style="text-align: left;">No formal studies have been conducted to investigate the effect of
renal impairment on the pharmacokinetics of mepolizumab. Based on
population pharmacokinetic analyses, no dose adjustment is required
in patients with creatinine clearance values between 50‑80 mL/min.
There are limited data available in patients with creatinine clearance
values &lt;50 mL/min.</p><p id="d3470ae2d-d28e-4d29-b522-f013f44fb629" style="text-align: left;"><i>Hepatic impairment</i></p><p id="p102612301717496844" style="text-align: left;">No formal studies
have been conducted to investigate the effect of hepatic impairment
on the pharmacokinetics of mepolizumab.  Since mepolizumab is degraded
by widely distributed proteolytic enzymes, not restricted to hepatic
tissue, changes in hepatic function are unlikely to have any effect
on the elimination of mepolizumab.</p></section>
<section id="dcd58c70b-f0dc-4969-8058-4b4c5add361c" level="1"><header id="d019e8b9d-4eef-4993-bdf2-aa1e49a1fdd9" style="text-align: left;"><b>6.   NONCLINICAL PROPERTIES</b></header><p id="db132eefb-4cd2-4c5f-bab1-523e0062a20a" style="text-align: left;">As mepolizumab is a monoclonal
antibody, no genotoxicity or carcinogenicity studies have been conducted.</p><p id="de1baffb1-2230-4b70-9d1b-ab5bb5aa8438" style="text-align: left;"><b>6.1.
 Animal Toxicology or Pharmacology</b></p><p id="d0a649b84-ac81-4325-a21b-d0520c5df42e" style="text-align: left;">Non-clinical data reveal
no special hazards for humans based on conventional studies of safety
pharmacology or repeated dose toxicity studies in monkeys. Intravenous
and subcutaneous administration to monkeys was associated with reductions
in peripheral and lung eosinophil counts, with no toxicological findings.</p><p id="dec442ad1-2097-4eb0-9df0-6d85a617b4a0" style="text-align: left;">Eosinophils
are thought to be associated with immune system responses to some
parasitic infections.  Studies conducted in mice treated with anti-IL-5
antibodies or genetically deficient in IL-5 or eosinophils have not
shown impaired ability to clear parasitic infections. The relevance
of these findings for humans is unknown.</p><p id="d583087fa-2096-4341-9f92-011e7caf3727" style="text-align: left;"><b><i>Fertility</i></b></p><p id="d352aabb5-ee24-4166-a26b-9af34b2dc52e" style="text-align: left;">No impairment of fertility
was observed in a fertility and general reproduction toxicity study
in mice performed with an analogous antibody that inhibits IL-5 in
mice. This study did not include a littering or functional offspring
assessment.</p><p id="d238849f6-60b9-4be0-b42d-d82ef8d22974" style="text-align: left;"><b><i>Pregnancy</i></b></p><p id="p102702301717496970" style="text-align: left;">In monkeys,
mepolizumab had no effect on pregnancy or on embryonic/fetal and postnatal
development (including immune function) of the offspring. Examinations
for internal or skeletal malformations were not performed. Data in
cynomolgus monkeys demonstrate that mepolizumab crossed the placenta.
Concentrations of mepolizumab were about 1.2‑2.4 times higher in infants
than in mothers for several months post partum and did not affect
the immune system of the infants.</p></section>
<section id="d8f316287-b707-4326-a87e-c69b7c184214" level="1"><header id="DESCRIPTION-FD14D4E4" style="text-align: left;"><b>7.   DESCRIPTION</b></header><p id="p873013301717497016" style="text-align: left;">Each vial contains 100 mg mepolizumab.
After reconstitution, each ml of solution contains 100 mg mepolizumab.<i> See section 2. Qualitative and Quantitative composition.</i><i> </i></p></section>
<section id="de2505e76-9a87-4b4c-b85e-792b61dcc9a3" level="1"><header id="d644d2493-0a6c-4af5-a218-b4c6b9a51cdb" style="text-align: left;"><b>8.   PHARMACEUTICAL PARTICULARS</b></header><p id="d0b829f80-7ac9-4f64-8a95-ee6304019c0d" style="text-align: left;"><b>8.1.  Incompatibilities</b></p><p id="db9a413b6-ff75-46a2-aeca-56a81f090150" style="text-align: left;">This medicinal product must not be mixed with other medicinal products.</p><p id="d1c0791b7-dfdd-40ee-a8aa-de9145ef2e92" style="text-align: left;"><b>8.2.
 Shelf Life</b></p><p id="d490e7c43-e8c9-46a1-b1ad-8755ed894731" style="text-align: left;"> 48 months.</p><p id="d9dffb93c-f71a-4566-9086-906d75e6b90d" style="text-align: left;"><b><i>After reconstitution</i></b></p><p id="d1f219393-a72c-4917-86d6-9fab84d5b057" style="text-align: left;">Chemical and physical stability
of the reconstituted medicinal product have been demonstrated for
8 hours when stored below 30°C.</p><p id="d40e6c8c6-354c-4ee8-8471-97e72ce7b757" style="text-align: left;">From a microbiological
point of view, unless the method of reconstitution precludes the risk
of microbial contamination, the product should be used immediately.
If not used immediately, in-use storage times and conditions are the
responsibility of user<i>.</i></p><p id="d6fc70105-4080-4dc8-8fe8-ae39d0a60992" style="text-align: left;">The expiry date is indicated
on the label and packaging.</p><p id="d54416438-d85a-440b-aa97-7ceed5ab7379" style="text-align: left;"><b>8.3.  Packaging Information</b></p><p id="d16c10076-e736-46c1-a961-52a2ac910291" style="text-align: left;">Clear, colourless 10 mL type I glass vial, with bromobutyl rubber
stopper and a grey aluminium overseal with a plastic flip-cap containing
100 mg powder for solution for injection.</p><p id="PackSizes1VialMultipackComprising33-FD15353F" style="text-align: left;">Pack sizes:<br/>1 vial<br/>Multipack comprising 3 (3 packs of 1) vials</p><p id="d4e2ed5ef-8e61-40c5-a479-16554db4950c" style="text-align: left;">All pack presentations
may not be marketed in the country.</p><p id="d057ae6ae-b781-411c-9574-86675ae72533" style="text-align: left;"><b>8.4.  Storage and
Handling Instructions</b></p><p id="dec3212cc-c996-46c8-a1c5-dfaa1adcbbf6" style="text-align: left;">Store between 2°C and 8°C.</p><p id="d9272748e-06ce-4797-93fb-2b6351be072a" style="text-align: left;">Do not freeze.</p><p id="d14ce149c-8620-4d75-a70b-41355a676a2f" style="text-align: left;">Keep the vial
in the outer carton in order to protect from light.</p><p id="da71b28e7-7dcd-4f6e-98a4-9417a194d3b5" style="text-align: left;">For storage conditions
after reconstitution of the medicinal product, see section <i> 8.2. Shelf Life</i>. </p><p id="db4d974b1-8ccc-4b0e-bb04-5426cab9627a" style="text-align: left;">Keep out of reach of children.</p><p id="d704625ea-1ff3-4bba-9cd8-94fc704f398e" style="text-align: left;"><b>8.5.
 Special precautions for disposal and other handling</b></p><p id="dd03d5ecc-c584-4481-8814-21e03bb23b99" style="text-align: left;"><i>NUCALA</i>  does not contain a preservative therefore reconstitution should
be carried out under aseptic conditions.</p><p id="ded2c35bc-d61a-4fd0-9207-acbd972a77f4" style="text-align: left;"><b><i>Instructions
for reconstitution</i></b></p><ol data-type="decimal" id="l102872301717497808">
<li data-enum="1."><b>Reconstitute the contents of the vial with 1.2 mL
of sterile water for injection </b>preferably using a 2 to 3 mL
syringe and a 21gauge needle. The stream of sterile water should be
directed vertically, onto the centre of the lyophilised cake. Allow
the vial to sit at room temperature during reconstitution, gently
swirling the vial for 10 seconds with circular motion at 15-second
intervals until the powder is dissolved.<br/><p id="NoteTheReconstitutedSolutionMustNot-FD178F67" style="text-align: left;margin-top:1.2pt;margin-bottom:1.2pt;"><i>Note: The
reconstituted solution </i><b><i>must not be shaken</i></b><i> during the procedure as this may lead to product
foaming or precipitation. Reconstitution is typically complete within
5 minutes after the sterile water has been added, but it may take
additional time. </i></p></li>
<li data-enum="2.">If a mechanical reconstitution device (swirler) is used
to reconstitute <i>NUCALA</i>, reconstitution can be accomplished
by swirling at 450 rpm for no longer than 10 minutes. Alternatively,
swirling at 1000 rpm for no longer than 5 minutes is acceptable.</li>
<li data-enum="3.">Following reconstitution, <i>NUCALA</i> should
be visually inspected for particulate matter and clarity prior to
use.  The solution should be clear to opalescent, and colourless to
pale yellow or pale brown, free of visible particles. Small air bubbles,
however, are expected and acceptable. If particulate matter remains
in the solution or if the solution appears cloudy or milky, the solution
must not be used. </li>
<li data-enum="4.">The reconstituted solution, if not used immediately must
be :<ul id="l107823301717499316">
<li data-enum="•">Protected from sunlight </li>
<li data-enum="•">Stored below 30°C, not frozen</li>
<li data-enum="•">Discarded if not used within 8 hours of reconstitution</li>
</ul></li>
</ol><p id="d3428e77a-19b6-4261-810b-957ae5c87f69" style="text-align: left;"><b><i>Instructions for administration</i></b></p><ol data-type="decimal" id="l77113301717499430">
<li data-enum="1.">For subcutaneous administration a 1 mL polypropylene syringe
fitted with a disposable needle 21 gauge to 27 gauge x 0.5 inch (13
mm) should preferably be used.</li>
<li data-enum="2.">Just prior to administration, remove 1 mL of reconstituted <i>NUCALA</i>.  Do not shake the reconstituted solution during
the procedure as this could lead to product foaming or precipitation.</li>
<li data-enum="3.">Administer the 1 mL injection (equivalent to 100 mg mepolizumab)
subcutaneously into the upper arm, thigh, or abdomen.</li>
</ol><p id="dc81231ea-9a83-4de8-a6c3-94572543baff" style="text-align: left;"><u>Disposal</u></p><p id="p1053615301717499548" style="text-align: left;">Any unused medicinal product or waste material should be disposed
of in accordance with local requirements.</p></section>
<section id="d2fe5a17b-a0b7-4e40-9484-309a29e87081" level="1"><header id="df7dd7019-d800-4740-8f1d-11daa9ab4ba9" style="text-align: left;"><b>9.   PATIENT COUNSELLING INFORMATION</b></header><p id="p1103812301717499642" style="text-align: left;">Registered
Medical Practitioners may counsel their patients (and/or patient’s
caregiver as applicable) about the special warnings and precautions
for use, drug interactions, undesirable effects, and any relevant
contraindications of <i>NUCALA 100 mg</i>. Patients (and/or
patient’s caregiver) may also be informed about posology, method of
administration and storage/handling information as applicable.</p></section>
<section id="dcdc22a4d-24de-4233-bbc0-934ff033f40a" level="1"><header id="DETAILSOFMANUFACTURER-FD188C13" style="text-align: left;"><b>10.   DETAILS OF MANUFACTURER </b></header><p id="d6634aa9d-55a2-44dd-9592-8dda60479176" style="text-align: left;">GlaxoSmithKline Manufacturing
S.p.A., <br/>Strada Provinciale Asolana,90 43056 San Polo di
Torrile,<br/>Parma, Italy-43056</p><p id="d2a48555f-8dde-4573-9dc8-4e17ad07aec1" style="text-align: left;">For further information
please contact:</p><p id="dc89f7cbf-6f0a-4aa9-b083-579806e0e7a5" style="text-align: left;">GlaxoSmithKline Pharmaceuticals
Limited<br/><b>Registered Office:</b><br/>Dr Annie
Besant Road, Worli, <br/>Mumbai 400 030, India.</p></section>
<section id="d15c2fbd0-1b06-4c68-b542-acb91ae23a26" level="1"><header id="d4b4a37c1-c7d0-458f-b8e5-fea0d4cb265f" style="text-align: left;"><b>11.   DETAILS OF PERMISSION OR
LICENSE NUMBER WITH DATE</b></header><p id="dcafa078f-5732-47e3-8966-5b7ea16f7e50" style="text-align: left;">Marketing Authorization
Holder:</p><p id="d70662266-8b89-4530-a39e-556e04606a73" style="text-align: left;"><b>Registered Office:</b><br/>GlaxoSmithKline
Pharmaceuticals Limited, <br/>Dr. Annie Besant Road, <br/>Worli, Mumbai 400 030, India<b>.</b></p><p id="MarketingAuthorizationNumberForm45I-FD18F9E1" style="text-align: left;">Marketing Authorization
number (Form 45): IMP-147/2018<br/>Date of first authorization
(Form 45): 12<sup>th</sup> June, 2018</p></section>
<section id="d54b2485f-c713-44f8-92a7-e59c2adf4b4f" level="1"><header id="DATEOFREVISION-FD18FFA7" style="text-align: left;"><b>12.   DATE OF REVISION</b></header><p id="d135dfc72-1e1d-4b25-a830-755c88211e5b" style="text-align: left;"><b>13-July-2023</b></p><p id="d6b79832c-0fa1-4ebe-b61b-193c285678c3" style="text-align: left;">Trade marks are owned by or licensed to the GSK group of companies.</p><p id="dfbf68337-5cf3-4847-9a48-85fc01924b43" style="text-align: left;"><i>Version
NUC/PI/IN/2023/01 dated 13 July 2023 </i></p><p id="dad28b7c2-5d21-4979-9f3a-b4f9045f9c1b" style="text-align: left;"><i>Adapted from</i> <i>EU SmPC dated 11 Oct 2022.</i></p></section>
</document>
